IXO+A in mCRC With Liver-only Metastases
A Single-arm Phase II Downsizing Study of Irinotecan, Capecitabine and Oxaliplatin (IXO) and Bevacizumab as First-line Treatment to Assess Conversion to Resectability of Liver-only Metastases in Colorectal Cancer Patients With Initially Unresectable Metastases
The percentage of patients with defined unresectable metastatic disease who will benefit from a first-line treatment enabling secondary complete metastasectomy is unknown but limited. Definition of optimized treatment algorithms is difficult due to very inhomogeneous patient populations.
This open label, multicentre Phase II study primarily aims to assess the resection rate achievable in a selected patient population with initially unresectable metastatic disease limited to the liver only in order to evaluate feasibility, safety and efficacy with regards to secondary resection of hepatic lesions in these patients.
The trial aims to enrol only patients meeting defined criteria of unresectability with regards to their hepatic lesions and will exclude patients with extrahepatic lesions in order to examine the most appropriate, highly active treatment regimen for this group of unresectable patients with the highest probability of a successful secondary metastasectomy with curative intent. The trial will be conducted in highly specialized centres with a track record of successful interdisciplinary treatment approaches in the field of metastatic colorectal cancer to allow the precise assessment of the peri-operative safety parameters as well as an evaluation of the surgical treatment approaches.
The IXO regimen selected for this study has shown in a phase I/II study promising efficacy and a favourable safety profile. Bevacizumab has demonstrated a significant survival benefit in combination with chemotherapy in metastatic colorectal cancer. Therefore the study will allow evaluation of its potential benefit in combination with the two most active current chemotherapy regimens in the first-line and post-operative treatment setting.
연구 개요
연구 유형
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Ontario
-
Ottawa, Ontario, 캐나다, K1H 8L6
- The Ottawa Hospital Cancer Center
-
Toronto, Ontario, 캐나다, M4N 3M5
- Sunnybrook Health Sciences Centre
-
Toronto, Ontario, 캐나다, M5T 2S8
- University Health Network
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3A 1A1
- McGill University Health Centre
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Primary colorectal cancer with unresectable metastatic lesion(s)
- At least one measurable lesion, confirmed by CT scan
- Male and female patients, aged ≥ 18 years
- ECOG performance score of 0 or 1 (within 1 week of study treatment start)
- Written informed consent
- Adequate general condition, cardiopulmonary functions and performance status
- Liver metastases no initially foreseen R0 resection of all hepatic lesions, but deemed potentially resectable after response to downsizing therapy
Exclusion Criteria:
- Extrahepatic metastatic disease
- Prior systemic or local treatment for metastatic disease, prior therapy with a biologic agent, prior adjuvant or neo-adjuvant chemotherapy, prior radiotherapy to the liver, other concurrent chemotherapy
- Inadequate bone marrow, liver, renal function, uncontrolled hypertension
- Pregnancy or lactation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: IXO+A
IXO regimen with Avastin
|
IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
conversion to resectability during downsizing therapy with IXO+A patients with initially unresectable liver-only metastases associated with colorectal cancer
기간: after 8 IXO+A cycles
|
after 8 IXO+A cycles
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Recurrence-free survival (RFS)
기간: Every 2 cycles
|
Every 2 cycles
|
|
Progression-free survival (PFS)
기간: Every 2 cycles
|
Every 2 cycles
|
|
Time to response (TTR)
기간: Every 2 cycles
|
Every 2 cycles
|
|
Overall survival (OS)
기간: Every 2 cycles
|
Every 2 cycles
|
|
Pathological complete response (pCR) rate
기간: assessed post-operatory
|
assessed post-operatory
|
|
Overall response rate (ORR)
기간: Every 2 cycles
|
Every 2 cycles
|
|
Number of participants with Adverse Events as a measure of Safety and Tolerability
기간: Every 3 weeks
|
Every 3 weeks
|
|
Surgical safety (frequency of surgical complications)
기간: assessed post-operatory
|
assessed post-operatory
|
|
Pathological changes in the non-tumoural liver following therapy with IXO+A
기간: assessed post-operatory
|
assessed post-operatory
|
|
R0, R1, R2 resection rate after up to 8 cycles of downsizing therapy with IXO+A
기간: assessed post-operatory
|
assessed post-operatory
|
공동 작업자 및 조사자
수사관
- 연구 의자: Jean Maroun, MD, The Ottawa Hospital Cancer Centre
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- OTT 10-01
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .